Company intelligence / Profile preview

MicroHarvest

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Successfully launched a pilot plant in November 2023, with plans for commercial launch of their first product in early 2024. Recent achievements include scaling production to 10 tons per day in a single vessel and launching a novel aquafeed pilot plant in Portugal in March 2025.

Modalities: Microbial proteinSingle-cell protein
Industry: Non-Drug Biotech

Drug pipeline

2 assets

Hilix MPX

Commercial

Indications: Pet food

1 more asset in the full pipeline.

Request access →

Partnerships

Contract manufacturer partnership confirmedPortuguese animal nutrition company

Beyond the preview

Go deeper on MicroHarvest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroHarvest.

Explore the full profile